KRAS and neoplasm: Since the multigene panel used in this study included all currently known predictors of anti-EGFR therapy resistance, including oncogenic mutations in KRAS, NRAS, BRAF and PIK3CA [30], the multigene MassARRAY analysis platform might be useful for monitoring genetic changes in the tumor population of metastatic CRC patients receiving anti-EGFR therapy.